218 related articles for article (PubMed ID: 23352917)
1. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
[TBL] [Abstract][Full Text] [Related]
2. Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Abaid LN; Brown Iii JV; Wilcox AM; Goldstein BH
Int J Hyperthermia; 2015 Feb; 31(1):8-14. PubMed ID: 25559985
[TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
[TBL] [Abstract][Full Text] [Related]
4. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
van der Vange N; van Goethem AR; Zoetmulder FA; Kaag MM; van de Vaart PJ; ten Bokkel Huinink WW; Beijnen JH
Eur J Surg Oncol; 2000 Nov; 26(7):663-8. PubMed ID: 11078613
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
Carrabin N; Mithieux F; Meeus P; Trédan O; Guastalla JP; Bachelot T; Labidi SI; Treilleux I; Rivoire M; Ray-Coquard I
Bull Cancer; 2010 Apr; 97(4):E23-32. PubMed ID: 20202920
[TBL] [Abstract][Full Text] [Related]
6. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
Lentz SS; Miller BE; Kucera GL; Levine EA
Gynecol Oncol; 2007 Jul; 106(1):207-10. PubMed ID: 17498782
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.
Fagotti A; Costantini B; Petrillo M; Vizzielli G; Fanfani F; Margariti PA; Turco LC; Piovano E; Scambia G
Gynecol Oncol; 2012 Dec; 127(3):502-5. PubMed ID: 23022234
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
[TBL] [Abstract][Full Text] [Related]
11. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study.
Spiliotis J; Vaxevanidou A; Sergouniotis F; Lambropoulou E; Datsis A; Christopoulou A
J BUON; 2011; 16(1):74-9. PubMed ID: 21674853
[TBL] [Abstract][Full Text] [Related]
12. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
[TBL] [Abstract][Full Text] [Related]
13. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
Ceelen WP; Van Nieuwenhove Y; Van Belle S; Denys H; Pattyn P
Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
[TBL] [Abstract][Full Text] [Related]
14. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
15. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
16. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
Harrison LE; Bryan M; Pliner L; Saunders T
Ann Surg Oncol; 2008 May; 15(5):1407-13. PubMed ID: 18157576
[TBL] [Abstract][Full Text] [Related]
18. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
Fagotti A; Costantini B; Vizzielli G; Perelli F; Ercoli A; Gallotta V; Scambia G; Fanfani F
Gynecol Oncol; 2011 Aug; 122(2):221-5. PubMed ID: 21543112
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK
Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
Helm CW; Randall-Whitis L; Martin RS; Metzinger DS; Gordinier ME; Parker LP; Edwards RP
Gynecol Oncol; 2007 Apr; 105(1):90-6. PubMed ID: 17173957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
